Acer Therapeutics Inc is a biotechnology business based in the US. Acer Therapeutics shares (ACER) are listed on the NASDAQ and all prices are listed in US Dollars. Acer Therapeutics employs 21 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Acer Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ACER – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Acer Therapeutics stock price (NASDAQ: ACER)Use our graph to track the performance of ACER stocks over time.
Acer Therapeutics shares at a glance
|Latest market close||$2.93|
|52-week range||$2.15 - $5.84|
|50-day moving average||$2.73|
|200-day moving average||$3.08|
|Wall St. target price||$10.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.20|
Buy Acer Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Acer Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Acer Therapeutics price performance over time
|1 week (2021-07-25)||N/A|
|1 month (2021-07-02)||2.45%|
|3 months (2021-05-05)||7.72%|
|6 months (2021-02-01)||N/A|
|1 year (2020-08-01)||N/A|
|2 years (2019-08-01)||N/A|
|3 years (2018-08-01)||N/A|
|5 years (2016-08-01)||N/A|
Acer Therapeutics financials
|Revenue TTM||$4 million|
|Gross profit TTM||$0|
|Return on assets TTM||-39.64%|
|Return on equity TTM||-158.78%|
|Market capitalisation||$34.6 million|
TTM: trailing 12 months
Shorting Acer Therapeutics shares
There are currently 45,327 Acer Therapeutics shares held short by investors – that's known as Acer Therapeutics's "short interest". This figure is 9.1% down from 49,883 last month.
There are a few different ways that this level of interest in shorting Acer Therapeutics shares can be evaluated.
Acer Therapeutics's "short interest ratio" (SIR)
Acer Therapeutics's "short interest ratio" (SIR) is the quantity of Acer Therapeutics shares currently shorted divided by the average quantity of Acer Therapeutics shares traded daily (recently around 64752.857142857). Acer Therapeutics's SIR currently stands at 0.7. In other words for every 100,000 Acer Therapeutics shares traded daily on the market, roughly 700 shares are currently held short.
However Acer Therapeutics's short interest can also be evaluated against the total number of Acer Therapeutics shares, or, against the total number of tradable Acer Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acer Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Acer Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0057% of the tradable shares (for every 100,000 tradable Acer Therapeutics shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acer Therapeutics.
Find out more about how you can short Acer Therapeutics stock.
Acer Therapeutics share dividends
We're not expecting Acer Therapeutics to pay a dividend over the next 12 months.
Have Acer Therapeutics's shares ever split?
Acer Therapeutics's shares were split on a 96:1000 basis on 20 September 2017. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 96 shares. This wouldn't directly have changed the overall worth of your Acer Therapeutics shares – just the quantity. However, indirectly, the new 941.7% higher share price could have impacted the market appetite for Acer Therapeutics shares which in turn could have impacted Acer Therapeutics's share price.
Acer Therapeutics share price volatility
Over the last 12 months, Acer Therapeutics's shares have ranged in value from as little as $2.15 up to $5.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acer Therapeutics's is 1.1796. This would suggest that Acer Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Acer Therapeutics overview
Acer Therapeutics Inc. , a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts. .
Stocks similar to Acer Therapeutics
Acer Therapeutics in the news
63 Biggest Movers From Friday
41 Stocks Moving In Friday's Mid-Day Session
20 Stocks Moving in Friday's Pre-Market Session
Frequently asked questionsWhat percentage of Acer Therapeutics is owned by insiders or institutions?
Currently 15.339% of Acer Therapeutics shares are held by insiders and 30.304% by institutions. How many people work for Acer Therapeutics?
Latest data suggests 21 work at Acer Therapeutics. When does the fiscal year end for Acer Therapeutics?
Acer Therapeutics's fiscal year ends in December. Where is Acer Therapeutics based?
Acer Therapeutics's address is: One Gateway Center, Newton, MA, United States, 02458 What is Acer Therapeutics's ISIN number?
Acer Therapeutics's international securities identification number is: US00444P1084 What is Acer Therapeutics's CUSIP number?
Acer Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00444P108
More guides on Finder
How to buy Chobani stock when it goes public
Everything we know about the Chobani IPO, plus information on how to buy in.
How to buy Stronghold Digital Mining (SDIG) stock when it goes public
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
How to buy ROX Financial LP (ROXA) stock when it goes public
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
Ask an Expert